Topical NMN for Hair Regrowth

Evidence Review created on 09/26/2026 using AI4L + evidence-mcp / Grok 4

Also known as: NMN, Nicotinamide Mononucleotide, β-NMN, β-Nicotinamide Mononucleotide, Topical Nicotinamide Mononucleotide

Motivation

Topical nicotinamide mononucleotide is a vitamin B3-related molecule applied to skin, including preparations aimed at thinning scalp hair. The interest is longevity biology, not a hormone blocker or a blood-pressure drug used on the scalp. It is a direct building block for a molecule cells use to transfer energy and run repair enzymes. Follicles are highly active, and that molecule declines with age.

Laboratory work is ahead of human trials. Applied to mouse skin after hair removal, in a model that uses the male hormone behind pattern hair loss, it was followed by earlier regrowth. Human follicle cells grown in a dish shifted growth-related signals in a favorable direction. The molecule can break down into a vitamin form that slowed human follicles studied outside the body. Oral administration is a different route and does not test a scalp preparation.

This review examines the proposed effect on hair regrowth, the mechanisms, the documented risks and quality record, and the human evidence. It presents that record. It does not set out a treatment plan.

Benefits - Risks - Protocol - Conclusion

This section points to high-level discussions of nicotinamide mononucleotide (NMN), a precursor of nicotinamide adenine dinucleotide (NAD+, the cofactor cells use for energy transfer and for enzymes that repair DNA), and to the main hair experiment.

The primary experiment of NMN applied to skin with a hair readout, plus follicle cells in a dish. It is the direct base for a topical hair claim, and it is not a human trial.

Compares oral NAD+, NMN, and nicotinamide riboside, precursors meant to raise NAD+, the same target as topical NMN. Hair regrowth is not an endpoint in the episode.

Long-form discussion of NMN as an NAD+ precursor and of why mouse oral doses translate poorly. It does not review a scalp preparation.

Sinclair describes NMN as the immediate precursor used to raise NAD+ in that group’s work. The conversation is longevity biology, not a topical hair product.

Reviews the oral Yoshino NMN trial on muscle insulin sensitivity. The shared target is NAD+, which NMN is meant to raise, and hair is not an endpoint.

Life Extension and Lifespan.io cover oral NMN in depth, and each has separate hair material, but neither reviews topical NMN for regrowth. With five items and one per outlet, they are not added. A member-only Peter Attia overview of NAD precursors is not linked; the free trial note above is. No priority source centered on a scalp preparation.

Grokipedia

Nicotinamide mononucleotide

The article summarizes oral NMN, NAD+ biology, published dose ranges, and the 2025 change in U.S. supplement status. It does not evaluate topical scalp use or hair regrowth.

Examine

Nicotinamide Mononucleotide

Collects oral dose ranges, trial grades, and safety gaps, including pregnancy and lactation. Topical scalp use and hair outcomes are outside the page’s scope.

ConsumerLab

NAD Booster Supplements Review (NAD+/NADH, Nicotinamide Riboside, and NMN)

Tests oral NAD+ boosters, including whether NMN products contain the labeled ingredient. The public summary does not cover topical hair preparations; detailed tables are for members.

Systematic Reviews

No systematic reviews or meta-analyses for Topical NMN were found on PubMed as of September 26, 2026.

Mechanism of Action

Topical NMN is applied to raise nicotinamide adenine dinucleotide (NAD+) in follicle cells. NAD+ carries electrons and is spent by sirtuins (proteins that change gene activity by removing acetyl groups) and by poly(ADP-ribose) polymerases (PARPs, enzymes that use NAD+ in DNA repair). The enzyme nicotinamide mononucleotide adenylyltransferase (NMNAT) converts NMN to NAD+. NMN is a water-soluble NMNAT substrate, not a selective receptor drug, and no plasma half-life after scalp use is published. On an artificial skin membrane it reached only the papillary dermis (upper inner skin) (Betsuno et al.).

In a dihydrotestosterone (DHT, the male hormone that shrinks susceptible follicles) model, 0.5% NMN on depilated (hair removed) mouse skin entered the growth phase earlier than DHT alone. Human dermal papilla cells (follicle-base cells) grown in a dish showed lower androgen receptor (AR, the protein DHT binds) and dickkopf-1 (DKK-1, a brake on Wnt, a growth signal), higher β-catenin (a Wnt signal protein) and vascular endothelial growth factor (VEGF, a signal for new small vessels), and less NF-κB (a master switch for inflammation) activity (Xu et al.). Sirtuin 7 (Sirt7, an NAD+-using enzyme) is required for mouse follicle stem cells to leave the resting state and falls with age (Li et al.).

NMN also breaks down in water to nicotinamide (vitamin B3), which slowed shaft growth and favored regression in human follicles kept outside the body (Haslam et al.). A degraded preparation can oppose that effect. An author of the mouse skin paper is employed by Guangdong Homy Genetics Ltd.

Historical Context & Evolution

NMN was characterized as a metabolic intermediate, not as a hair treatment. It is the last small precursor before NAD+ in the salvage pathway that recycles nicotinamide released by sirtuins, PARPs, and CD38 (an enzyme on immune-cell surfaces that breaks NAD+ down). Oral NMN later entered longevity research after mouse studies tied lower NAD+ to worse metabolic function. Human trials then tested oral administration for blood NAD+, insulin action, blood pressure, and muscle measures, not hair.

Hair entered through follicle stem-cell work. Sirt7, which uses NAD+, is required for mouse follicles to re-enter growth and is lower in aged follicles (Li et al.), though that experiment did not apply NMN. A later study put 0.5% NMN on depilated mouse skin in a DHT model and reported faster regrowth, with parallel tests in human dermal papilla cells grown in a dish (Xu et al.). The methods describe application to skin; one results sentence says the groups were injected, so the route wording is inconsistent. Commercial topical preparations followed the oral supplement market, not a hair-regrowth approval.

Nicotinamide, the vitamin NMN can become, has the opposite result in human follicles kept outside the body (Haslam et al.). Both can stand: NAD+ restoration and nicotinamide-driven regression describe different chemical states of one preparation. No professional body has issued a hair guideline for topical NMN. Industry authorship on the mouse paper, and the stake of NAD+ sellers, are reasons to read positive summaries against the primary experiments.

Expected Benefits

High 🟩 🟩 🟩

No benefit reaches High: a hair endpoint of topical NMN has not been shown in more than one human trial, and no such trial was found; the human-relevant material is cells in a dish plus one mouse skin experiment.

Medium 🟩 🟩

No benefit reaches Medium: there is no controlled human trial and no consistent observational cohort of topical NMN for hair regrowth.

Low 🟩

Speculative 🟨

Earlier growth-phase entry in mice

0.5% NMN on depilated mouse skin under DHT brought earlier regrowth than DHT alone, resembling 5% minoxidil, in six mice per group. An author is employed by Guangdong Homy Genetics Ltd. (Xu et al.).

Growth signals in human follicle cells

In human dermal papilla cells exposed to DHT, NMN lowered AR and DKK-1 readouts and raised VEGF and β-catenin. These are signals from a dish, not hair counts on a scalp (Xu et al.).

Stem-cell protection in an oxidative patchy-loss model

In an oxidative alopecia areata model (patchy autoimmune loss), NMN improved stem-cell survival via SIRT7 in cells and injured mice. It is not a human scalp trial (Cao et al.).

Benefit-Modifying Factors

  • Androgen exposure: The mouse and cell signals were produced under DHT. Follicles not under that androgen pressure may not show the same shift, and no human dose-response by hormone level exists.

  • Age: Sirt7 falls in aged mouse follicle stem cells, so the NAD+-linked step may matter more later in life. No topical NMN study has tested that age split.

  • Sex: The mouse hair experiment was not reported by sex. No topical human comparison of women and men exists, so a sex difference in regrowth is unshown.

  • Baseline labs: Iron deficiency and thyroid disease change shedding on their own. No study links a starting NAD+ level, ferritin, or thyroid value to a response from topical NMN.

  • Scalp access: Free NMN stayed in the papillary dermis of an artificial membrane. Thick scale, heavy sebum (skin oil), or a vehicle (the base that carries NMN) that never releases it would be expected to blunt any local effect.

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk reaches High: adverse events of topical NMN have not been recorded in more than one human trial, because no such trial was found.

Medium 🟥 🟥

No risk reaches Medium: a meta-analysis of oral trials did not find more adverse events in adults (Yang et al.), and that record is not a controlled or observational series of scalp application.

Low 🟥

Speculative 🟨

Slower follicle growth if the molecule breaks down

Nicotinamide, a breakdown product of NMN, slowed shaft growth and pushed human follicles toward regression outside the body at high concentration. Whether a scalp preparation reaches that exposure is untested (Haslam et al.).

Inflammatory output of old cells

Raising NAD+ increased inflammatory secretions from senescent cells (aged cells that no longer divide), a preclinical pattern tied to tumor promotion. Oral trials and scalp use have not shown it (Nacarelli et al.).

No studied exposure in pregnancy or lactation

No fetal or milk level has been measured for a scalp preparation. Not using it in those periods removes an exposure that has not been studied, rather than a documented injury.

Risk-Modifying Factors

  • Degraded product: Breakdown in water to nicotinamide is the step that connects a preparation to the result in which follicles kept outside the body slowed. Heat, water, and age of the preparation raise that chance.

  • Age: Senescent cells accumulate with age. The preclinical rise in their inflammatory secretions, if it occurs in scalp skin, would matter more in older adults. Human topical data do not show this.

  • Sex: No topical adverse-event series compares women and men. Oral safety pools are not a substitute for scalp irritation rates by sex.

  • Broken skin: Erosions, infection, or a fresh procedure would be expected to increase absorption and stinging relative to intact skin, which is the setting of the mouse application study.

  • Baseline labs: Ferritin and thyroid hormone levels are not known to change a topical adverse effect. Active scalp disease still changes background shedding, and topical NMN is untested on that background.

Key Interactions & Contraindications

  • Topical minoxidil: Caution. No interaction study exists. Both are leave-on scalp products, so irritation can add. Spacing applications is the practical separation when stinging occurs.

  • 5-alpha-reductase inhibitors (finasteride, dutasteride; drugs that lower DHT): Caution. No pharmacokinetic interaction (one drug changing how the body handles the other) is documented. Combined use is unstudied, so any added harm is unknown.

  • Oral NAD+ precursors (nicotinamide riboside, nicotinamide): Caution. Effects on NAD+ supply would be expected to add. Nicotinamide itself slowed human follicle growth outside the body, so stacking it is not a neutral add-on for hair.

  • Drugs and supplements that stress methylation (spending methyl groups; methotrexate, high-dose niacin): Caution, mainly for oral use. Nicotinamide is methylated before excretion. A topical course has no measured effect on that demand; oral stacking is where that is discussed.

Populations who should avoid Topical NMN:

  • Pregnancy: No human safety data. Examine rates avoidance as warranted. That is missing evidence, not a documented injury.
  • Lactation: No milk data. The same avoidance note applies. Transfer from a scalp film is unmeasured.

Risk Mitigation Strategies

  • Small-area trial first: A few days on a limited patch of intact scalp, before wider use, limits how much skin is exposed if redness or stinging appears.

  • Stability over a water-based preparation: An assayed β-NMN (beta form) content and a stated storage condition reduce breakdown to nicotinamide, the product linked to slower follicle growth outside the body.

  • Hold off over a known cancer: Higher NAD+ supply increased inflammatory secretions tied to tumor promotion in preclinical work. Not using the preparation there avoids that unmeasured exposure.

  • Separate leave-on products if irritation appears: No minoxidil interaction trial exists. Spacing applications lowers the chance of additive scalp irritation from two vehicles.

  • Pregnancy and lactation gap: No fetal or milk data exist. Not using the preparation in those periods removes an unmeasured exposure. This is absence of evidence, not a documented injury.

Therapeutic Protocol

  • No consensus human regimen: No leading clinic protocol for topical NMN and hair was identified. Published human hair trials of this route were not found.

  • Preclinical skin concentration: The mouse study applied 0.5% NMN daily to depilated skin and used 5% minoxidil as the comparator. That is not a transferred human dose (Xu et al.).

  • Time of day: Not studied for scalp NMN. The mouse application was once daily, without a clock-time comparison.

  • Body half-life: No plasma half-life after topical use is published. NMNAT converts NMN to NAD+ in one step. About 7 months at 20°C is shelf life in one filtrate, not body clearance (Betsuno et al.).

  • Single versus split application: Not studied on a scalp. The mouse regimen was a single daily skin application, not divided doses.

  • Genetic variants: No human variant is shown to set a topical dose. Axonal SARM1 (an enzyme that destroys NAD+ when NMN is high relative to NAD+) is a nerve pathway, not a follicle dosing rule.

  • Sex: The mouse hair readout was not stratified by sex. No evidence sets a different topical concentration for women or men.

  • Age: Lower Sirt7 in aged mouse follicles suggests the NAD+ step may matter more late in life. No age-specific topical concentration has been tested.

  • Baseline biomarkers: No NAD+, ferritin, or hormone threshold is known to predict a response. Those labs matter for other causes of shedding, not for picking an NMN percentage.

  • Existing scalp disease: The DHT model resembles pattern hair loss, and a separate oxidative model used patchy autoimmune loss. Neither is a proven human indication for topical use.

Discontinuation & Cycling

  • Intended duration: Unknown. The mouse exposure lasted days, not a lifetime plan. Nothing establishes that topical NMN must be continued for years or stopped after a course.

  • Withdrawal: No withdrawal syndrome is described. That absence reflects missing human stop-studies, not a demonstration of zero rebound shedding.

  • Taper: No taper schedule has been tested. There is no receptor-occupancy rationale, of the sort used for some hormonal drugs, that would require a staged reduction.

  • Cycling: Not studied. A hypothesis that follicles need continuous NAD+ support would argue against long gaps, but that hypothesis has no efficacy trial behind it.

Sourcing and Quality

  • Identity of β-NMN: The β form is the one used in the biologic literature. A third-party lab assay that separates and measures the ingredient is the check that a product contains NMN rather than a substitute or none of the labeled ingredient.

  • Documented identity testing: ConsumerLab’s NAD booster review reports that the oral products it tested, including NMN, contained the labeled ingredient. Topical hair preparations were not in that test.

  • Shelf stability: In one yeast-fermented filtrate, NMN had a half-life near 7 months at 20°C. Water, heat, and an aged preparation favor breakdown to nicotinamide (Betsuno et al.).

  • Penetration, not just percentage: Free NMN is water-soluble. Liposomal gels and microneedles are experimental delivery tools, not evidence that a cosmetic preparation reaches the follicle bulb (Ye et al., Sabbagh & Kim).

  • No ranked topical brands: Independent testing identified here covers oral NAD+ boosters. No equivalent public ranking of topical NMN hair preparations was found. A seller’s hair claim is not a quality assay.

Practical Considerations

  • Time to effect: In mice, skin darkening was described within days and short hair within about 10 days after hair removal. No human topical time course exists. Animal speed is not a forecast for scalp coverage.

  • Common pitfalls: Treating nicotinamide (niacinamide) as if it were NMN; reading an oral study as if it were a scalp trial; buying a water-based product with no assay; expecting the evidence standard of minoxidil.

  • Regulatory status: In the United States, regulators reversed an earlier exclusion and, as of late 2025, allowed NMN to be marketed as a dietary supplement. A claim to regrow hair can still place a topical preparation in drug territory rather than cosmetic territory.

  • Cost and access: Topical NMN is sold without a prescription and costs less than procedural restoration. Insurers usually cover neither cosmetic scalp products nor hair procedures, so payer incentives do not favor one over the other. Price does not track evidence.

Interaction with Foundational Habits

  • Sleep: Direction none. NAD+ metabolism intersects circadian biology in other tissues, but no scalp-NMN study has measured sleep time or sleep quality, so no interaction is shown.

  • Nutrition: Direction indirect. No diet is known to be required for a topical effect. Methyl donors such as folate and vitamin B12 are discussed for high-dose oral nicotinamide excretion, not for a localized scalp film.

  • Exercise: Direction none. No study shows blunting or potentiation of training adaptation. Sweat or an immediate post-exercise rinse could dilute a leave-on film; that is a practical timing note, not an efficacy finding.

  • Stress management: Direction indirect. Physiologic stress can push follicles into a shedding phase through pathways that topical NMN has not been shown to block. Stress reduction is a separate hair variable, not a demonstrated partner effect.

Monitoring Protocol & Defining Success

Before any reading of a topical preparation, baseline photographs and a same-site hair count separate product change from ordinary seasonal shed. Ferritin, thyroid-stimulating hormone (TSH, the pituitary signal that drives the thyroid), and 25-hydroxyvitamin D are included because iron deficiency, thyroid disease, and low vitamin D cause shedding a scalp film will not correct. Those labs are confounders, not NMN toxicity markers. No topical study has set a liver or metabolic panel schedule.

Ongoing checks are photographs and, where available, a phototrichogram (magnified hair count) at 12 weeks and then every 6 months. Labs repeat only if the baseline value was outside the range being tracked. Success, if it appears, is a change from the person’s own baseline, not a population normal.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Terminal hair density (thick scalp hairs) No established target; track change from the person’s own baseline Shows whether more thick scalp hairs are present Same site and lighting; phototrichogram if available. Population “normal” density varies too widely to use as a goal
Hair-shaft diameter No established target; track microns against the person’s own baseline Thinning shafts mark miniaturization (shafts shrinking) A shift of a few microns can be measurement noise. Pair with density, not alone
Ferritin 50–100 ng/mL Low iron stores cause shedding unrelated to the topical Conventional lower limits near 15–30 ng/mL are often too low when hair is the concern. Fasting is not required
TSH 0.5–2.5 mIU/L Thyroid excess or deficiency changes the hair cycle Many conventional ranges run about 0.4–4.5 mIU/L. Morning draw is preferable
25-hydroxyvitamin D 40–60 ng/mL Deficiency is a reversible contributor to shedding Conventional sufficiency cutoffs are often ≥20 or ≥30 ng/mL. Not a measure of NMN effect

Qualitative markers:

  • Shedding on wash or brush days, counted the same way each time
  • Scalp comfort: itch, redness, or flaking after application
  • Coverage on repeat photographs of the same part and hairline
  • Whether any change survives a planned break, which the discontinuation literature does not yet define

Emerging Research

Conclusion

Topical nicotinamide mononucleotide is a vitamin B3-related molecule applied to skin in the hope of restarting thinning scalp hair. The interest is a longevity one. Follicles are busy tissue, and the energy-transfer molecule this preparation feeds declines with age. That biology does not make a scalp preparation a proven way to regrow hair.

The regrowth signal comes from mice treated on the skin after hair removal, in a model that uses the male hormone behind pattern hair loss, and from human follicle cells grown in a dish. Those experiments moved growth-related signals in a favorable direction and lined up, in direction only, with a standard topical hair drug. They are not trials in people. A breakdown product slowed human follicles kept alive outside the body, so a preparation that degrades could work against itself. Combined short-term trials of oral administration looked tolerable in adults. That record does not measure the scalp.

Quality belongs in the same picture. Water-based preparations can lose the intact molecule, and free molecules of this type appear to penetrate skin only shallowly. A genetics company employed an author of the mouse skin experiment, and sellers of the ingredient have a commercial reason to favor positive readings. For a risk-aware adult focused on hair density over years, the record is a plausible follicle mechanism, a thin animal and cell base, and no controlled human demonstration that a scalp preparation regrows hair.

Top - Benefits - Risks - Protocol